ATP synthase c subunit lysine N-methyltransferaseGenealiases: FAM173B · JS-2 · hFAM173B
Q-omics provides the consensus-scored ATPSCKMT profile across patient tissues and cancer cell-line models. ATPSCKMT expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ATPSCKMT is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, ATPSCKMT RNA expression shows 18,988 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and LUAD as cancer lineages where ATPSCKMT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATPSCKMT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATPSCKMT survival associations across molecular data types. ATPSCKMT RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATPSCKMT RNA expression–survival associations across cancer types. High ATPSCKMT expression shows unfavorable associations in UVM, BRCA and LIHC, but favorable associations in KIRC, HNSC and OV. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ATPSCKMT RNA expression.
This table summarizes ATPSCKMT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ATPSCKMT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATPSCKMT shows lower tumor expression in THCA and higher tumor expression in LUAD, LIHC, HNSC, LUSC and STAD. The LUAD box plot shows higher ATPSCKMT RNA expression in tumor versus normal tissue (log2 FC = +0.967, t-test p < 0.001).
This table shows molecular features associated with ATPSCKMT in patient tissues and cancer cell lines. In patient samples, ATPSCKMT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ATPSCKMT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
